Skip to content

September 2026

September's research on uterine and endometrial cancer was rich in long-term results and practical guidance. The biggest headline came from the RUBY trial: after about four years, adding immunotherapy to chemotherapy continues to keep cancer under control for many people whose tumors have a feature called mismatch repair deficiency. Molecular testing of tumors kept moving from the lab into everyday decisions about surgery and treatment, and several studies looked at weight, insulin resistance, and earlier detection. The month also brought patient-centered work on quality of life, fertility-sparing treatment, and the factors behind racial and ethnic differences in survival.

The papers highlighted here represent a selection of those published during the month. The papers were selected and summarized by AI. Accuracy of the summaries was confirmed by a scientist. This digest incorporates only open-access research articles that are free to be read by the entire community and that are explicitly licensed to be shared and reused.

Knowing your tumor's molecular type is reshaping treatment choices

Endometrial cancers are now sorted into four molecular groups that predict how a tumor is likely to behave and which treatments are most likely to help. Asking about your tumor's molecular group is one of the most useful questions you can bring to your care team.

  • Two reviews agree that molecular testing adds useful information beyond what the microscope shows, and they describe what each group means for you. Tumors with a POLE mutation (a gene change in a DNA-copying enzyme) have an excellent outlook and may need less treatment. Tumors with mismatch repair deficiency, or MMR-d (a defect in the cell's DNA "spell-checking" system), respond strongly to immunotherapy. Tumors with abnormal p53 are the highest-risk group, and tumors with "no specific molecular profile" are the most varied. One review pooled 74 studies covering about 42,000 people and found that when a tumor carries more than one of these features, POLE generally takes priority, then MMR-d, then p53. Testing for POLE, MMR, and p53 is practice-ready; newer markers are still being studied. (Read the full paper) (Read the full paper)
  • In 575 people with early-stage endometrial cancer, about 1 in 10 had "substantial" lymphovascular space invasion (cancer cells found in many of the tiny lymph or blood vessels near the tumor), a feature now built into FIGO 2023 staging. MMR-d tumors had nearly three times the odds of showing it, and tumors growing deep into the uterine wall had about eight times the odds. This single-center study suggests molecular type and tumor depth together can sharpen decisions about follow-up treatment. (Read the full paper)

Check the citations section for a comprehensive list of publications associated with this topic.

Surgery, staging, and follow-up treatment continue to be refined

Researchers are working out which surgical steps and which treatment sequences give people the best chance of a lasting cure.

  • If you are diagnosed with a precancerous condition called endometrial intraepithelial neoplasia, or atypical hyperplasia, before surgery, a lymph node check during your hysterectomy may be worth discussing. In 86 people with this diagnosis, 57% turned out to have cancer once the uterus was examined, and sentinel lymph node mapping (a technique that finds and removes the first few lymph nodes where cancer would spread) found lymph node involvement in 11 people. The authors estimate that up to 8 of those 11 cases might have been missed if surgeons had waited for a quick during-surgery biopsy result before deciding. This was a retrospective, single-center study with no comparison group, so the authors recommend individual counseling rather than mapping everyone. (Read the full paper)
  • For people with stage III to IVA endometrial cancer, the order of chemotherapy and radiation after surgery may matter. A network meta-analysis combining 9 studies and 8,401 patients found that "sandwich" treatment (chemotherapy, then radiation, then more chemotherapy) was linked to better overall and progression-free survival than other sequences, without more severe side effects. Because the studies were mostly observational, the authors call for a prospective trial before this becomes standard. (Read the full paper)

Check the citations section for a comprehensive list of publications associated with this topic.

Immunotherapy is producing long-lasting results for some people with advanced disease

For advanced or recurrent endometrial cancer, the newest results show durable benefit in some groups and point to which tumors may respond to other targeted combinations.

  • If your advanced or recurrent cancer is MMR-d or MSI-high (a closely related lab finding), adding the immunotherapy drug dostarlimab to standard carboplatin and paclitaxel chemotherapy continues to show lasting benefit. After a median follow-up of about four and a half years in the phase 3 RUBY trial, the risk of death was 66% lower than with chemotherapy alone, and very few new progression events occurred in the extra follow-up period. A statistical model estimated that about half of patients treated with dostarlimab (54%) may have curative potential, a hopeful but still exploratory estimate. No new safety concerns appeared. This is practice-ready evidence. (Read the full paper)
  • For recurrent endometrial cancer, adding a third drug, ribociclib, to the two-drug combination of everolimus and letrozole did not improve progression-free survival for the group as a whole in a randomized phase 2 trial. However, among people who had already received hormone (endocrine) therapy, 61.5% responded with the three-drug combination compared with none with the two-drug combination. Within the three-drug group, tumors with a CTNNB1 gene change had longer disease control. These are early clinical findings that point to who might benefit most and need confirmation. (Read the full paper)

Check the citations section for a comprehensive list of publications associated with this topic.

Weight and metabolic health are part of the endometrial cancer story

Excess weight is a well-recognized risk factor for endometrial cancer, and this month's studies looked at insulin resistance and tested practical, supported ways to lose weight.

  • A medically supervised meal-replacement program before surgery was feasible for people with a body mass index (BMI) of 40 or higher and either atypical hyperplasia or low-grade endometrial cancer. Of 104 people who enrolled, 72 completed the program and lost an average of 15 kilograms (about 33 pounds) before surgery, and their weight stayed roughly stable over the following year. Patient interviews were part of the study. Larger studies are needed to show whether this improves surgery or cancer outcomes. (Read the full paper)
  • For premenopausal women living with obesity and at higher risk of breast and endometrial cancer, a 12-month total diet replacement program (a structured plan that replaces regular meals for 12 weeks, followed by gradual reintroduction of food) helped most participants lose weight. Of 47 women, 79% finished the program, with a median loss of about 8.4 kilograms at 12 months, along with better weight-related quality of life. This was an early, uncontrolled study; controlled trials are needed before it becomes routine. (Read the full paper)
  • In 168,431 UK Biobank participants, a higher triglyceride-glucose index (a simple measure of insulin resistance calculated from routine blood fat and blood sugar tests) was linked to a higher risk of developing endometrial cancer, especially among people with overweight or obesity. Part of the link between body weight and endometrial cancer appeared to run through insulin resistance. This is an observational association, not proof of cause, but it suggests metabolic health is a meaningful target for prevention research. (Read the full paper)

Check the citations section for a comprehensive list of publications associated with this topic.

Earlier detection and hereditary risk testing can find cancer sooner or prevent it

Most abnormal bleeding is not cancer, so better first tests could spare many people invasive procedures, while knowing about inherited risk can open the door to prevention.

  • If you are at increased risk of endometrial cancer and are weighing a risk-reducing hysterectomy (removing the uterus before cancer can develop), new data can help with that conversation. In a UK study, 1,001 women rated described health states after surgery. One year after hysterectomy alone, quality-of-life scores matched the general population, and they were only slightly lower when the ovaries and tubes were also removed. Scores were lower in the first month, as expected during recovery. (Read the full paper)
  • Four Japanese medical societies issued a joint statement supporting a "tumor-first" approach: testing every endometrial cancer for mismatch repair or microsatellite instability. This can identify Lynch syndrome (an inherited condition that raises the risk of colorectal, endometrial, and other cancers) and, at the same time, show who may benefit from immunotherapy. The statement also covers risk-reducing surgery, surveillance, and testing for relatives, and calls for equitable access to genetic counseling. (Read the full paper)
  • For people aged 45 and older with abnormal uterine bleeding, a lab test that reads chemical marks on DNA, called WID-qEC, may be a cheaper and gentler first step than transvaginal ultrasound. In a UK analysis, only 12% of people needed further definitive testing after WID-qEC, compared with 57% after ultrasound, and the test was very likely to save money at its expected price. (Read the full paper)
  • A review of proteins found in cervicovaginal fluid (fluid that can be collected from the vagina, much like a swab) identified three protein panels with promising accuracy for detecting endometrial cancer. These tests are still exploratory and need large prospective studies before they can be used in clinics. (Read the full paper)

Check the citations section for a comprehensive list of publications associated with this topic.

Younger patients have growing options to preserve fertility

For some people with very early endometrial cancer or atypical hyperplasia, treatment without removing the uterus is possible, and this month brought encouraging long-term and case-level results.

  • If you are considering fertility-sparing treatment with a hormone-releasing intrauterine device (a levonorgestrel IUD), long-term follow-up from the feMMe trial is reassuring. Among 44 participants surveyed a median of about five years after starting treatment, overall quality of life was favorable and did not differ by treatment group, whether the cancer came back, or whether they later had a hysterectomy. Most (85%) would recommend the treatment. The group was small and the analysis descriptive. (Read the full paper)
  • A case report described a young woman with Lynch syndrome-associated endometrial cancer whose cancer did not fully respond to standard progestin hormone therapy. A combination including a PD-1 inhibitor (a type of immunotherapy) led to complete remission, and embryo genetic testing then allowed her to have a healthy baby without the family's inherited gene change. This is a single case, so it shows what may be possible, not what to expect. (Read the full paper)

Check the citations section for a comprehensive list of publications associated with this topic.

Quality of life is becoming a core measure of treatment success

How you feel during and after treatment matters as much as scans and survival numbers, and researchers are paying closer attention to it.

  • A systematic review of the major first-line trials for advanced endometrial cancer found that newer immunotherapy-based treatments generally maintained quality of life, and in some cases helped. In RUBY, dostarlimab plus chemotherapy delayed lasting declines in quality of life for people with MMR-d tumors; in DUO-E, physical functioning improved in the MMR-d subgroup. The authors note that quality-of-life results are often reported late and inconsistently, and call for better standards. (Read the full paper)

Check the citations section for a comprehensive list of publications associated with this topic.

Uterine sarcomas and rare subtypes are getting more focused attention

Uterine sarcomas and rare carcinoma types behave differently from common endometrial cancer and often need their own treatment approach. Much of this month's work in this area is listed by citation only.

  • Primary endometrial neuroendocrine carcinoma is a rare, aggressive type of endometrial cancer. In 17 people treated in Japan, more than half were diagnosed at an advanced stage and median survival was 16 months. Notably, 41% of these tumors were MMR-d, a higher rate than in other subtypes, which suggests immunotherapy could become an important part of first treatment. This small retrospective study needs confirmation. (Read the full paper)

Check the citations section for a comprehensive list of publications associated with this topic.

Epidemiology, access, and health disparities research

Who you are and where you live still shape outcomes, and this month's studies help explain why.

  • Among more than 14,000 insured people with uterine cancer treated in the same US health care system, Black patients had about twice the risk of dying within five years compared with White patients. Most of that gap (about 71%) was explained by differences in tumor characteristics, such as higher-risk tumor types, and about 21% by socioeconomic factors; differences in other health conditions, diagnosis, and treatment quality did not explain it. The authors conclude that closing the gap will require better treatments for high-risk tumor types and support that addresses socioeconomic barriers. (Read the full paper)
  • In a national database of 4,322 people with endometrial cancer who received immunotherapy from 2019 to 2022, survival for non-Hispanic Black patients was similar to that of non-Hispanic White patients, even though Black patients more often had serous tumors, an aggressive subtype. Hispanic patients, however, had worse survival, which the authors say cannot be explained only by unequal access to newer treatments. (Read the full paper)
  • In the Nordic countries, endometrial cancer in women under 50 rose by 36% over two decades, from 1.4 to 1.9 cases per 100,000 person-years. Deaths in this age group stayed very low, and five-year survival remained high at 90% to 95%. The authors point to obesity prevention as an important strategy for younger women. (Read the full paper)

Check the citations section for a comprehensive list of publications associated with this topic.

General and basic-science uterine cancer research

Laboratory and early-stage studies this month explored how endometrial cancer cells grow, spread, and might be targeted in the future. None of this work is ready for patient care yet, but it is where tomorrow's treatments begin, and the published papers are listed so you can follow them.

Check the citations section for a comprehensive list of publications associated with this topic.

What Does This Mean for Me?

Do I know my tumor's molecular type? Testing for POLE, mismatch repair, and p53 is now part of standard care in many places, and the results can change how much treatment you need and which treatments are most likely to work. If your tumor is MMR-d, testing can also point to Lynch syndrome, which matters for you and your relatives. You might ask: "Has my tumor been tested for its molecular type, and how do the results affect my treatment plan?"

If my cancer is advanced or has come back, is immunotherapy an option? For people with MMR-d or MSI-high tumors, four-year RUBY results show that adding immunotherapy to chemotherapy can keep cancer under control for a long time, without making quality of life worse. Other combinations are being studied for tumors without this feature. You might ask: "Is my tumor MMR-d or MSI-high, and which immunotherapy or targeted options fit my situation?"

Can changes to my weight or metabolic health make a difference? This month's studies show that supervised weight-loss programs are achievable for many people and that insulin resistance is linked to endometrial cancer risk. The research does not yet show that weight loss changes cancer outcomes, but it suggests that support for metabolic health is worth discussing. You might ask: "Is there a supervised nutrition or weight-management program that could support me before or after treatment?"

This digest is prepared by OCRA (Ovarian Cancer Research Alliance) for patients, caregivers, and advocates. It is intended to inform, not to guide individual treatment decisions. Please speak with your care team about what research findings may mean for your specific situation.

Sources

The citations below are grouped to match the sections above. "Directly referenced" papers are the ones summarized in that section; the remaining entries are on-topic papers that were either not discussed above or are behind access restrictions.

Knowing your tumor's molecular type is reshaping treatment choices

Directly referenced:

1. Marchetti M, et al. "Personalizing endometrial cancer care beyond histology: clinical applications and limits of molecular classification." Int J Gynecol Cancer. September 2026. PMID 42617416. https://doi.org/10.1016/j.ijgc.2026.104882

2. Chinaliyeva G, et al. "Molecular Classification of Endometrial Cancer in the Era of Precision Oncology: Prognostic Significance, Emerging Biomarkers, and Personalized Therapeutic Strategies-A Systematic Review." Diagnostics (Basel). September 9, 2026. PMID 42793688. https://doi.org/10.3390/diagnostics16182902

3. Öncü HN, et al. "Association of immunohistochemically defined molecular subtypes with substantial lymphovascular space invasion in early-stage endometrial cancer: a single-center cohort of 575 patients." J Gynecol Oncol. September 2, 2026. PMID 42725695. https://doi.org/10.3802/jgo.2026.37.e156

Additional open-access citations:

4. Szatkowski W, et al. "Molecular Profile of Advanced Endometrial Cancer (FIGO III-IV) in a Polish Multicentre Cohort: Clinicopathological Characterisation and Treatment Implications." J Clin Med. September 11, 2026. PMID 42795824. https://doi.org/10.3390/jcm15187051 (open access, molecular profile of advanced disease in a Polish multicenter cohort)

5. Xiao Y, et al. "Heterogeneity in Clinicopathological and PD-L1 Expression Profiles Across Mismatch Repair Protein Deficiency Patterns in Endometrial Carcinoma." Cancers (Basel). September 11, 2026. PMID 42794913. https://doi.org/10.3390/cancers18182946 (open access, mismatch repair loss patterns and PD-L1 expression)

6. Yoon H, et al. "Evaluation of HER2 status in endometrial carcinoma using endometrial, gastric, and breast cancer criteria: focus on HER2-low." J Gynecol Oncol. September 2026. PMID 41906783. https://doi.org/10.3802/jgo.2026.37.e86 (open access, HER2 scoring criteria and HER2-low status)

7. Backhaus C, et al. "Expression of HER2 Ultralow in Endometrial Carcinoma, High-Grade Serous Ovarian Cancer and Their Metastases." Cancers (Basel). September 2, 2026. PMID 42738364. https://doi.org/10.3390/cancers18172843 (open access, HER2-ultralow expression in primary tumors and metastases)

Related citations, access restricted:

8. Uppin M, et al. "Molecular subtyping and POLE mutation spectrum in endometrial carcinoma." Indian J Med Res. September 2026. PMID 42690860. https://doi.org/10.25259/IJMR_2714_2025 (restricted license, CC BY-NC-SA 4.0)

9. Xia W, et al. "Interpretation strategy of POLE, mismatch repair deficiency, and p53 in the multiple molecular classification of endometrial carcinoma and its clinical differences from single classification: a retrospective cohort study." Eur J Obstet Gynecol Reprod Biol. September 2026. PMID 42492478. https://doi.org/10.1016/j.ejogrb.2026.115324 (license unconfirmed)

10. Favier A, et al. "Beyond p53 status: the continued importance of histopathologic features for predicting lymph node metastasis in endometrial cancer." Int J Gynecol Cancer. September 2026. PMID 42435643. https://doi.org/10.1016/j.ijgc.2026.104820 (subscription access)

11. Fanfani F, et al. "The PROMISE-EC Study: prognostic role of molecular classification and sentinel lymph node status in early-stage endometrial cancer." Int J Gynecol Cancer. September 2026. PMID 42378721. https://doi.org/10.1016/j.ijgc.2026.104796 (subscription access)

12. Eldegwi S, et al. "Integration of L1CAM and β-catenin immunohistochemistry for prognostic risk stratification of endometrial carcinoma: a practical approach for resource-limited settings." Med Mol Morphol. September 2026. PMID 42286151. https://doi.org/10.1007/s00795-026-00464-4 (subscription access)

13. Scarpelli E, et al. "Redefining endometrial cancer phenotypes in the era of molecular classification and sentinel lymph node mapping: results from a multicenter Italian study." Int J Gynecol Cancer. September 2026. PMID 41667298. https://doi.org/10.1016/j.ijgc.2026.104502 (subscription access)

14. Silk T, et al. "Molecular characterization of NSMP endometrial cancer and its relevance for treatment." Gynecol Oncol. September 2, 2026. PMID 42685640. https://doi.org/10.1016/j.ygyno.2026.08.017 (subscription access)

15. Houlal A, et al. "POLD1 and Endometrial Cancer: Molecular Mechanisms, Genomic Pathology, and Emerging Therapeutics." Int J Gynecol Pathol. September 2, 2026. PMID 42684934. https://doi.org/10.1097/PGP.0000000000001211 (subscription access)

Surgery, staging, and follow-up treatment continue to be refined

Directly referenced:

16. Bakır MS, et al. "Sentinel Lymph Node Mapping Without Intraoperative Frozen Section in Preoperative Endometrial Intraepithelial Neoplasia/Atypical Endometrial Hyperplasia: Feasibility, Diagnostic Yield, and the Estimated Consequence of Frozen-Section Triage." Curr Oncol. September 21, 2026. PMID 42782916. https://doi.org/10.3390/curroncol33090570

17. Chen X, et al. "Adjuvant sandwich therapy is associated with improved survival in stage III-IVA endometrial cancer: a network meta-analysis." J Gynecol Oncol. September 2026. PMID 42108734. https://doi.org/10.3802/jgo.2026.37.e100

Additional open-access citations:

18. Cengiz M, et al. "Perioperative Risk Stratification in Surgically Treated Endometrial Cancer: The Impact of Nutritional Status and Comorbidity Burden on Morbidity and Survival." Ann Surg Oncol. September 2026. PMID 42228263. https://doi.org/10.1245/s10434-026-19906-5 (open access, nutrition and comorbidity scores and surgical risk in older patients)

19. Xin L, et al. "Annual hazard rates for early-stage endometrial carcinoma after postoperative radiotherapy under FIGO 2023 staging system: results from a population-based single-center cohort study." J Gynecol Oncol. September 2026. PMID 42135962. https://doi.org/10.3802/jgo.2026.37.e107 (open access, yearly recurrence risk after postoperative radiotherapy under FIGO 2023)

Related citations, access restricted:

20. Cui Y, et al. "Functional MRI parametric map-based radiomics nomograms for preoperative risk stratification of early-stage endometrial cancer: A multicenter study." Magn Reson Imaging. September 1, 2026. PMID 42679868. https://doi.org/10.1016/j.mri.2026.110785 (subscription access)

21. Makinoda C, et al. "Laparoscopic Resection of Vaginal Cuff Recurrence Following Surgery for Endometrial Cancer." Tokai J Exp Clin Med. September 20, 2026. PMID 42669945. https://pubmed.ncbi.nlm.nih.gov/42669945/ (license unconfirmed)

22. Bahrehmand K, et al. "[The role of sentinel lymph node biopsy in the management of gynecologic cancers: current evidence and institutional experience]." Magy Onkol. September 2026. PMID 42731005. https://pubmed.ncbi.nlm.nih.gov/42731005/ (free to read, no reuse license)

23. Hattori K, et al. "Sacrum Metastasis in Stage IA Endometrial Carcinoma 13 Years After Surgery: A Case Report." J Obstet Gynaecol Res. September 2026. PMID 42733225. https://doi.org/10.1111/jog.70493 (subscription access)

24. Jiang Y, et al. "Integrated virtual MR elastography and IVIM-DWI for preoperative prediction of lymph-vascular space invasion in endometrial cancer." Clin Radiol. September 2026. PMID 42541941. https://doi.org/10.1016/j.crad.2026.107434 (subscription access)

25. Bahçeci P, et al. "Clinicopathologic prognostic factors and the role of adenomyosis in endometrial cancer: A 25-year single-center experience." Eur J Obstet Gynecol Reprod Biol. September 2026. PMID 42398213. https://doi.org/10.1016/j.ejogrb.2026.115284 (subscription access)

26. Qin Z, et al. "Predictors of Bilateral Sentinel Lymph Node Mapping Failure in Endometrial Cancer: A Systematic Review and Meta-Analysis." J Minim Invasive Gynecol. September 2026. PMID 42167542. https://doi.org/10.1016/j.jmig.2026.05.013 (subscription access)

27. Manetti V, et al. "Improving Postoperative Acute Pain Management and Accelerating Discharge: The Role of the ERAS Pathway in Overweight Patients Undergoing Endometrial Cancer Surgery." J Pain Palliat Care Pharmacother. September 2026. PMID 42127158. https://doi.org/10.1080/15360288.2026.2666277 (license unconfirmed)

28. Veiga N, et al. "Improved prognostic stratification with the FIGO 2023 endometrial cancer staging system. A multicenter Spanish cohort study." Int J Gynaecol Obstet. September 2026. PMID 41854156. https://doi.org/10.1002/ijgo.70951 (subscription access)

29. Li W, et al. "Working in concert: radiology, pathology, and gynecologic oncology applications of the 2023 FIGO updates in endometrial cancer staging." Abdom Radiol (NY). September 2026. PMID 41774132. https://doi.org/10.1007/s00261-026-05437-w (subscription access)

30. Tam K, et al. "Management of medically inoperable low-grade endometrial cancer: patterns of care and outcomes with radiation, brachytherapy, and hormonal therapy." Int J Gynecol Cancer. September 2026. PMID 41723063. https://doi.org/10.1016/j.ijgc.2026.104496 (subscription access)

31. Delso V, et al. "Prognostic value of cervical involvement in advanced endometrial cancer." Int J Gynecol Cancer. September 2026. PMID 41680022. https://doi.org/10.1016/j.ijgc.2026.104489 (subscription access)

32. Acs M, et al. "The evolving role of open abdominal surgery in gynecological malignancies in the era of minimally invasive and precision oncology." World J Surg Oncol. September 7, 2026. PMID 42706566. https://doi.org/10.1186/s12957-026-04510-4 (license unconfirmed)

Immunotherapy is producing long-lasting results for some people with advanced disease

Directly referenced:

33. Powell MA, et al. "Four-year survival outcomes with dostarlimab plus chemotherapy in mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer in the RUBY trial." Gynecol Oncol. September 2026. PMID 42215378. https://doi.org/10.1016/j.ygyno.2026.05.008

34. How JA, et al. "Efficacy of everolimus and letrozole with or without ribociclib in recurrent endometrial cancer: a phase 2 randomized clinical trial." Nat Commun. September 1, 2026. PMID 42823426. https://doi.org/10.1038/s41467-026-77049-3

Additional open-access citations:

35. Moiola CP, et al. "A mouse PDX clinical trial reveals broad efficacy of niraparib and vc-seco-DUBA anti-HER2 ADC SYD985 in HER2/neu expressing endometrial cancer." Biomed Pharmacother. September 2026. PMID 42551191. https://doi.org/10.1016/j.biopha.2026.119830 (open access, mouse study of niraparib and an anti-HER2 antibody-drug conjugate)

36. Lin PH, et al. "Frontline immunotherapy and immune cold reprogramming across molecular subtypes of advanced endometrial cancer." Cancer Lett. September 2026. PMID 42241805. https://doi.org/10.1016/j.canlet.2026.218652 (open access, review of frontline immunotherapy across molecular subtypes)

37. Casas-Arozamena C, et al. "Longitudinal circulating tumor DNA profiling in patients with advanced endometrial cancer using an off-the-shelf targeted NGS panel." Mol Oncol. September 2026. PMID 42047179. https://doi.org/10.1002/1878-0261.70246 (open access, circulating tumor DNA monitoring in advanced disease)

38. Jaafar H, et al. "Advanced endometrial cancer in the gulf cooperation council: a modified-Delphi consensus on unmet needs, molecular testing, and treatment sequencing." Front Oncol. September 24, 2026. PMID 42851344. https://doi.org/10.3389/fonc.2026.1916197 (open access, Gulf region expert consensus on testing and treatment sequencing)

39. Jing S, et al. "The economic value of mismatch repair-guided immunotherapy in endometrial cancer: companion testing and patient selection." Front Med (Lausanne). September 9, 2026. PMID 42781119. https://doi.org/10.3389/fmed.2026.1951624 (open access, economic value of mismatch repair testing to guide immunotherapy)

Related citations, access restricted:

40. Manning WB, et al. "IMMU-NO versus yes: Applicability of immune checkpoint inhibitors in gynecologic cancers." Cancer. September 15, 2026. PMID 42745396. https://doi.org/10.1002/cncr.70611 (subscription access)

41. Zhou L, et al. "Cadonilimab plus lenvatinib in advanced endometrial cancer: the multicenter single-arm phase II CLEAR-EC trial." Nat Commun. September 4, 2026. PMID 42838953. https://doi.org/10.1038/s41467-026-77467-3 (restricted license, CC BY-NC-ND 4.0)

42. Nguyen AQ, et al. "Feedback activation of MAPK-ERK1/2 signaling causes resistance to trastuzumab-deruxtecan in endometrial cancers." Gynecol Oncol. September 2026. PMID 42594534. https://doi.org/10.1016/j.ygyno.2026.08.005 (subscription access)

43. De Tommasi O, et al. "Integrated expression profiling of trophoblast cell-surface antigen 2 (TROP2), folate receptor alpha (FRα), and human epidermal growth factor receptor 2 (HER2) in endometrial Cancer across molecular classes, genomic alterations, and histologic subtypes." Gynecol Oncol. September 2026. PMID 42567118. https://doi.org/10.1016/j.ygyno.2026.08.002 (subscription access)

44. Kabirian R, et al. "Efficacy and safety of immune checkpoint inhibitor rechallenge in cervical and endometrial cancer: a multi-center retrospective study (RICE study)." Int J Gynecol Cancer. September 2026. PMID 42538280. https://doi.org/10.1016/j.ijgc.2026.104867 (subscription access)

45. Kuchar M, et al. "Stevens-Johnson syndrome precipitating days after treatment for dostarlimab-induced autoimmune encephalitis: a case report." Gynecol Oncol Rep. September 24, 2026. PMID 42835466. https://doi.org/10.1016/j.gore.2026.102219 (restricted license, CC BY-NC-ND 4.0)

46. Lee JY, et al. "E7386 plus lenvatinib in patients with advanced endometrial cancer that progressed on platinum-based chemotherapy and an anti-PD-(L)1 immunotherapy: a single-arm, open-label, global phase 1b/2 dose-expansion cohort." EClinicalMedicine. September 23, 2026. PMID 42830785. https://doi.org/10.1016/j.eclinm.2026.104206 (restricted license, CC BY-NC-ND 4.0)

47. Mandarano de Mattos J, et al. "How long is enough? Immunotherapy duration in mismatch repair deficient endometrial cancer." Int J Gynecol Cancer. September 2026. PMID 42378723. https://doi.org/10.1016/j.ijgc.2026.104797 (subscription access)

48. Han C, Zhang P. "Response to immuno-targeted therapy in recurrent endometrial carcinoma." Int J Gynecol Cancer. September 2026. PMID 41905846. https://doi.org/10.1016/j.ijgc.2026.104642 (subscription access)

Weight and metabolic health are part of the endometrial cancer story

Directly referenced:

49. Aubrey C, et al. "The feasibility of a medically supervised preoperative weight loss program in patients with obesity and atypical hyperplasia, or low-grade endometrial carcinoma." Gynecol Oncol. September 2026. PMID 42551137. https://doi.org/10.1016/j.ygyno.2026.07.024

50. Clarke H, et al. "Adherence and weight loss with a total diet replacement programme for increased cancer risk associated with obesity: a UK cohort study." BMJ Open. September 28, 2026. PMID 42805663. https://doi.org/10.1136/bmjopen-2026-119498

51. Shen Y, et al. "The triglyceride-glucose index as a measure of insulin resistance and risk of incident endometrial cancer: a prospective analysis in UK Biobank." J Gynecol Oncol. September 2026. PMID 42135960. https://doi.org/10.3802/jgo.2026.37.e102

Related citations, access restricted:

52. Chen Y, et al. "Obesity promotes aggressiveness of endometrial cancer via metabolic reprogramming and intercellular crosstalk in the tumor microenvironment." Cancer Lett. September 2026. PMID 42250754. https://doi.org/10.1016/j.canlet.2026.218649 (subscription access)

53. Harrington S, et al. "The role of metabolic and bariatric surgery for obesity management in endometrial intraepithelial neoplasia and endometrial cancer: A Society of Gynecologic Oncology and Society of American Gastrointestinal and Endoscopic Surgeons clinical practice statement." Gynecol Oncol. September 2026. PMID 42579945. https://doi.org/10.1016/j.ygyno.2026.07.016 (subscription access)

54. Cengiz M, et al. "Concomitant Metabolic Bariatric Surgery and Minimally Invasive Hysterectomy for Endometrial Cancer or Endometrial Intraepitelhelial Neoplasia in Patients with Severe Obesity: A Systematic Review of Early Experience." Obes Surg. September 2026. PMID 42479408. https://doi.org/10.1007/s11695-026-08848-2 (subscription access)

55. Wang SE, et al. "Premenopausal and postmenopausal obesity and endometrial cancer risk: circulating biomarkers of inflammation, insulin resistance, and sex hormones as mediators." J Natl Cancer Inst. September 1, 2026. PMID 42015885. https://doi.org/10.1093/jnci/djag119 (subscription access)

Earlier detection and hereditary risk testing can find cancer sooner or prevent it

Directly referenced:

56. Oxley S, et al. "Health-related quality of life after risk-reducing hysterectomy: a randomised vignette study." Gynecol Oncol. September 2026. PMID 42570385. https://doi.org/10.1016/j.ygyno.2026.07.021

57. Sato S, et al. "Clinical utility of diagnosing Lynch syndrome in gynecologic oncology: a joint statement from four Japanese academic societies." Int J Clin Oncol. September 2026. PMID 42435282. https://doi.org/10.1007/s10147-026-03126-8

58. Snowsill TM, et al. "Cost-Minimization Analysis of the Women's Cancer Risk Identification-Quantitative Polymerase Chain Reaction Test for Endometrial Cancer Epigenetic Biomarker Compared With Transvaginal Ultrasound for Triaging Abnormal Uterine Bleeding." Value Health. September 2026. PMID 41962837. https://doi.org/10.1016/j.jval.2026.03.2235

59. Njoku K, et al. "Protein signatures for the early detection of endometrial cancer in cervico-vaginal fluid." Expert Rev Mol Diagn. September 2026. PMID 42460670. https://doi.org/10.1080/14737159.2026.2705465

Additional open-access citations:

60. Xie CH, Cao HR. "Lymphocyte markers with CA125 and HE4 for diagnosing early endometrial cancer in postmenopausal women: case-control study." J Obstet Gynaecol. September 11, 2026. PMID 42726666. https://doi.org/10.1080/01443615.2026.2719764 (open access, blood lymphocyte markers with CA125 and HE4 for early diagnosis)

Related citations, access restricted:

61. Han L, et al. "[Predictive value of a combined prediction model for pathologic upgrade to endometrial carcinoma after hysterectomy in patients with endometrial hyperplasia]." Zhonghua Fu Chan Ke Za Zhi. September 25, 2026. PMID 42802112. https://doi.org/10.3760/cma.j.cn112141-20260421-00221 (license unconfirmed)

62. Çeçen Dönmez Y, et al. "Diagnostic and prognostic significance of serum phoenixin-14 and phoenixin-20 levels in patients with endometrial cancer." Biomarkers. September 2026. PMID 42554038. https://doi.org/10.1080/1354750X.2026.2715761 (subscription access)

63. Alcázar JL, et al. "Role of three-dimensional ultrasound in the diagnosis and staging of gynecological malignancies: Focus on endometrial and cervical cancer." Best Pract Res Clin Obstet Gynaecol. September 2026. PMID 42508374. https://doi.org/10.1016/j.bpobgyn.2026.102758 (subscription access)

64. Abbass MA, et al. "Extent of Surgery in Lynch Syndrome Associated Colorectal Cancer and Endometrial Cancer Risk Reduction: Seeing the Forest for the Trees." Clin Colon Rectal Surg. September 2026. PMID 42553833. https://doi.org/10.1055/a-2760-7548 (free to read, no reuse license)

Younger patients have growing options to preserve fertility

Directly referenced:

65. Steger K, et al. "Quality of life and patient-reported outcomes after non-surgical management of early-stage endometrial cancer and endometrial hyperplasia with atypia: a long-term follow-up of the feMMe phase II randomized clinical trial." Int J Gynecol Cancer. September 2026. PMID 42413196. https://doi.org/10.1016/j.ijgc.2026.104806

66. Zhao Y, et al. "Case Report: Immunotherapy-containing fertility-sparing treatment integrated with preimplantation genetic testing resulting in live birth in Lynch syndrome-associated endometrial cancer." Front Oncol. September 11, 2026. PMID 42798460. https://doi.org/10.3389/fonc.2026.1942599

Related citations, access restricted:

67. Cokan A, et al. "Biomarkers guiding fertility-sparing treatment in endometrial cancer." Int J Gynecol Cancer. September 2026. PMID 42531777. https://doi.org/10.1016/j.ijgc.2026.104839 (subscription access)

68. Xiao B, et al. "Calcium dysregulation in synergy with sonodynamic therapy via medroxyprogesterone-targeted and ROS-responsive nanoparticles for endometrial cancer." Bioact Mater. September 23, 2026. PMID 42830878. https://doi.org/10.1016/j.bioactmat.2026.09.017 (restricted license, CC BY-NC-ND 4.0)

Quality of life is becoming a core measure of treatment success

Directly referenced:

69. Tuninetti V, et al. "Quality of life in first-line trials for endometrial cancer: A systematic review." Tumori. September 29, 2026. PMID 42811691. https://doi.org/10.1177/03008916261468178

Related citations, access restricted:

70. Buda A, et al. "Nodal staging in endometrial cancer: quality of life, patient-reported outcomes, and survivorship." Int J Gynecol Cancer. September 2026. PMID 42430890. https://doi.org/10.1016/j.ijgc.2026.104787 (subscription access)

71. Zhang T, et al. "Comparison of the EORTC QLQ-EN24, FACT-En, and FEnSI-23 for assessing quality of life in endometrial cancer: a systematic review." Curr Opin Support Palliat Care. September 2026. PMID 42213858. https://doi.org/10.1097/SPC.0000000000000805 (subscription access)

72. Sudilovsky GM, et al. "Exploring decision-making preferences around treatment in patients with advanced and recurrent uterine cancer." Int J Gynecol Cancer. September 2026. PMID 42470721. https://doi.org/10.1016/j.ijgc.2026.104834 (subscription access)

73. Bağlar İ, et al. "Electronic Health Literacy and Health-Related Quality of Life in Endometrial Cancer Survivors: A Cross-Sectional Study." J Health Commun. September 21, 2026. PMID 42765560. https://doi.org/10.1080/10810730.2026.2733190 (subscription access)

74. Yu CH, et al. "Factors associated with sexual quality of life among endometrial cancer survivors: A cross-sectional study." Eur J Oncol Nurs. September 16, 2026. PMID 42762590. https://doi.org/10.1016/j.ejon.2026.103324 (subscription access)

Uterine sarcomas and rare subtypes are getting more focused attention

Directly referenced:

75. Hiranuma K, et al. "Frequency of mismatch repair deficiency for primary endometrial neuroendocrine carcinoma and its therapeutic outcome in Japan." Taiwan J Obstet Gynecol. September 2026. PMID 42642148. https://doi.org/10.1016/j.tjog.2026.04.017

Additional open-access citations:

76. Yang S, et al. "Sintilimab‑related cystitis/ureteritis in high‑grade endometrial stromal sarcoma: A case report and structured literature review." Hum Vaccin Immunother. September 9, 2026. PMID 42714310. https://doi.org/10.1080/21645515.2026.2707681 (open access, case report of an immunotherapy bladder side effect in endometrial stromal sarcoma)

77. Ito T, et al. "Durable disease control following multidisciplinary treatment including pembrolizumab in POLE-mutated dedifferentiated endometrial carcinoma with brain metastases: A case report." Medicine (Baltimore). September 18, 2026. PMID 42760661. https://doi.org/10.1097/MD.0000000000050714 (open access, case report of durable control in POLE-mutated dedifferentiated carcinoma)

Related citations, access restricted:

78. Miserotti L, et al. "[Exceptional cardiopulmonary triad revealing an endometrial stromal sarcoma]." Rev Med Liege. September 2026. PMID 42751836. https://pubmed.ncbi.nlm.nih.gov/42751836/ (license unconfirmed)

79. Qi Y, et al. "Dedifferentiated/undifferentiated endometrial carcinoma:SWI/SNF-deficiency and molecular heterogeneity indicating novel prognostic stratification in a single-center study of 71 cases." Hum Pathol. September 2026. PMID 42162929. https://doi.org/10.1016/j.humpath.2026.106155 (subscription access)

80. Alzayadneh E, et al. "HER2 and FOLR1 Expression in Mesonephric and Mesonephric-Like Adenocarcinomas in the Gynecologic Tract." Int J Gynecol Pathol. September 2026. PMID 42095344. https://doi.org/10.1097/PGP.0000000000001187 (subscription access)

81. Chen Q, et al. "Collision Tumor of the Uterine Corpus: Primary EBV-positive Diffuse Large B-Cell Lymphoma and Endometrioid Carcinoma." Int J Gynecol Pathol. September 2026. PMID 41212936. https://doi.org/10.1097/PGP.0000000000001146 (subscription access)

82. Lai YL, et al. "Association between pembrolizumab-based therapy exposure and survival outcomes in metastatic or recurrent uterine carcinosarcoma: a multi-center real-world study." Int J Gynecol Cancer. September 2026. PMID 42613237. https://doi.org/10.1016/j.ijgc.2026.104869 (subscription access)

83. Lee GM, et al. "Advances in uterine sarcoma management: A mini-review of clinical practice and molecular insights." Gynecol Oncol Rep. September 22, 2026. PMID 42835191. https://doi.org/10.1016/j.gore.2026.102217 (restricted license, CC BY-NC-ND 4.0)

84. Aybek SD, et al. "In vitro evaluation of the Anticarcinogenic effects of zerumbone in the SK-UT-1 human uterine Leiomyosarcoma cell line." Mol Biol Rep. September 23, 2026. PMID 42776289. https://doi.org/10.1007/s11033-026-12811-w (subscription access)

85. Hindman N, et al. "How I Do It: Identifying Signs to Differentiate Uterine Sarcoma (Leiomyosarcoma) from Leiomyomas at MRI." Radiology. September 2026. PMID 42770820. https://doi.org/10.1148/radiol.252877 (subscription access)

86. Odintsov I, et al. "Clinicopathologic Study of 39 Mismatch Repair-deficient Sarcomas Demonstrates Recurrent Histologic Patterns and Supports Universal Screening of Pleomorphic Rhabdomyosarcoma, Uterine Leiomyosarcoma, and Undifferentiated and Unclassified Sarcomas." Am J Surg Pathol. September 2026. PMID 42281350. https://doi.org/10.1097/PAS.0000000000002579 (subscription access)

87. Sun BJ, et al. "Efficacy and Safety of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Recurrent Uterine Leiomyosarcoma: Results of a Phase 2 Study." Ann Surg Oncol. September 2026. PMID 42104036. https://doi.org/10.1245/s10434-026-19777-w (subscription access)

Epidemiology, access, and health disparities research

Directly referenced:

88. Suh-Burgmann EJ, et al. "Factors accounting for excess uterine cancer mortality among insured Black versus White patients treated within the same US health care system." Int J Gynecol Cancer. September 2026. PMID 41794556. https://doi.org/10.1016/j.ijgc.2026.104589

89. Mecklai K, et al. "The Impact of Racial and Ethnic Background on Overall Survival in Endometrial Cancer Patients Receiving Immunotherapy as Front-Line Treatment." Cancers (Basel). September 9, 2026. PMID 42794880. https://doi.org/10.3390/cancers18182914

90. Riese C, et al. "Incidence, prevalence, mortality and survival trends in women with endometrial-, ovarian- and cervical cancer in the Nordic countries (1980-2023) with focus on younger women (0-49 years old)." Gynecol Oncol. September 2026. PMID 42617581. https://doi.org/10.1016/j.ygyno.2026.08.014

Additional open-access citations:

91. Zheng P, et al. "Psychiatric disorders and gynecologic tumors: A 2-sample Mendelian randomization study of 20 exposure-outcome pairs." Medicine (Baltimore). September 18, 2026. PMID 42760730. https://doi.org/10.1097/MD.0000000000050669 (open access, genetic study of psychiatric disorders and gynecologic tumor risk)

92. Nakamura K, et al. "Examining the relationship between cesarean section scar and endometrial cancer." J Gynecol Oncol. September 2026. PMID 41958175. https://doi.org/10.3802/jgo.2026.37.e96 (open access, cesarean section scar and endometrial cancer)

Related citations, access restricted:

93. Hong JY, et al. "Disparities in the Diagnosis and Treatment of Endometrial Cancer Among People with Disabilities." Int J Gynecol Cancer. September 2026. PMID 42520501. https://doi.org/10.1016/j.ijgc.2026.104851 (subscription access)

94. Casarin J, et al. "Surgical volume, structural quality, and compliance with European Society of Gynaecological Oncology quality indicators in endometrial and cervical cancer: a regional cross-sectional assessment." Int J Gynecol Cancer. September 2026. PMID 42501475. https://doi.org/10.1016/j.ijgc.2026.104847 (subscription access)

95. Kasuya K, et al. "Guideline-concordant treatment and clinical outcomes in older patients with endometrial cancer in Japan: a retrospective single-institution study." Int J Clin Oncol. September 2026. PMID 42490006. https://doi.org/10.1007/s10147-026-03113-z (license unconfirmed)

96. de la Motte Rouge T, et al. "Real-world outcomes and management of endometrial cancer in France from 2016 to 2021 (MOONBEAM study)." Bull Cancer. September 2026. PMID 42321049. https://doi.org/10.1016/j.bulcan.2026.03.019 (subscription access)

97. Eaglehouse YL, et al. "Age Comparisons of Endometrial Cancer Clinicopathology and Treatment in the United States Military Health System." Mil Med. September 1, 2026. PMID 41678719. https://doi.org/10.1093/milmed/usag023 (subscription access)

98. Yuan Q, et al. "Radiotherapy for female non-gynecologic pelvic and adjacent cancers and secondary uterine Cancers: a SEER analysis." Radiother Oncol. September 2026. PMID 42471142. https://doi.org/10.1016/j.radonc.2026.111697 (subscription access)

99. McPherson GS, et al. "Pacific women's pre-diagnostic experiences of endometrial cancer across the Auckland region: a qualitative study using talanoa." J Prim Health Care. September 24, 2026. PMID 42778165. https://doi.org/10.1071/HC26095 (restricted license, CC BY-NC-ND 4.0)

General and basic-science uterine cancer research

Additional open-access citations:

100. Shu C, et al. "Cisplatin combined with high-intensity focused ultrasound inhibits endometrial cancer progression by inducing pyroptosis." Int J Hyperthermia. September 26, 2026. PMID 42799609. https://doi.org/10.1080/02656736.2026.2705285 (open access, laboratory study of cisplatin with focused ultrasound)

101. Jin Y, et al. "Translational Progress of Inorganic Nanotheranostic Platforms for Gynecologic Malignancies: A Narrative Review of Endometrial, Ovarian, and Cervical Cancer Focusing on Fertility Preservation, Biosafety, and Industrial Translation." Int J Nanomedicine. September 16, 2026. PMID 42769022. https://doi.org/10.2147/IJN.S642254 (open access, review of inorganic nanomaterials for gynecologic cancers)

102. Ulger G, et al. "Prognostic Value of Preoperative Inflammatory, Hematological, and Metabolic Blood Indices in Endometrioid-Type Endometrial Cancer: A Retrospective Cohort Study." Medicina (Kaunas). September 14, 2026. PMID 42796373. https://doi.org/10.3390/medicina62091767 (open access, preoperative blood indices and prognosis)

103. Dadas Y, et al. "Comprehensive Bioinformatic and miRNA-Driven Analysis of the Multimeric Canonical I Kappa B Kinase (IKK) Complex in Uterine Corpus Endometrial Carcinoma (UCEC)." Biomolecules. September 8, 2026. PMID 42793128. https://doi.org/10.3390/biom16091296 (open access, bioinformatic analysis of the IKK signaling complex)

104. Chuwa AH, Mvunta DH. "Immunometabolic interactions in gynecologic cancers: Mechanisms, biomarkers, and therapeutic implications." J Int Med Res. September 16, 2026. PMID 42750153. https://doi.org/10.1177/03000605261476189 (open access, review of immune and metabolic interactions in gynecologic cancers)

105. Marques LF, et al. "Beyond Tumor-Intrinsic STAT3: Integrating Metabolic and Immune Communication in the Tumor Microenvironment of Cervical, Ovarian, and Endometrial Cancers." Cancers (Basel). September 14, 2026. PMID 42794927. https://doi.org/10.3390/cancers18182960 (open access, review of STAT3 signaling in the tumor microenvironment)

106. Zhang J, et al. "Engineered exosomes with RNA-motif short hairpin RNA loading and Rab4-boosted production enable controlled ferroptosis in endometrial carcinoma." Bioeng Transl Med. September 2026. PMID 42666679. https://doi.org/10.1002/btm2.70163 (open access, engineered exosomes to trigger tumor cell death in the lab)

Related citations, access restricted:

107. Zhang M, et al. "AMPK/mTOR/ULK1-mediated cytotoxic autophagy synergizes with apoptosis to drive the anti-endometrial cancer efficacy of platinum nanoclusters." Biomater Adv. September 6, 2026. PMID 42727515. https://doi.org/10.1016/j.bioadv.2026.215162 (subscription access)

108. Estrada-Estrada E, et al. "Analysis of changes in the phenotypic profile and frequencies of peripheral blood myeloid-derived suppressor cells in patients with endometrial cancer before and after surgical treatment." Cell Immunol. September 6, 2026. PMID 42715880. https://doi.org/10.1016/j.cellimm.2026.105153 (subscription access)

109. Zhang JY, et al. "[Endometrial cancer: current clinical issues, unmet needs, and future research directions]." Zhonghua Yi Xue Za Zhi. September 29, 2026. PMID 42778313. https://doi.org/10.3760/cma.j.cn112137-20260601-01426 (license unconfirmed)

110. Mohamed ASAE, et al. "Immunohistochemical evaluation of androgen receptor expression in endometrial carcinoma and its clinicopathological significance." Diagn Pathol. September 26, 2026. PMID 42791571. https://doi.org/10.1186/s13000-026-01848-x (license unconfirmed)

111. Sun W, et al. "Fgl-1 promotes the progression of endometrial adenocarcinoma through PI3K/AKT signal pathway." Med Oncol. September 15, 2026. PMID 42742877. https://doi.org/10.1007/s12032-026-03375-7 (subscription access)

112. Li F, et al. "DHCR24 promotes endometrial carcinoma progression and is associated with cellular senescence regulation." Med Oncol. September 15, 2026. PMID 42742784. https://doi.org/10.1007/s12032-026-03406-3 (subscription access)

113. Yu H, et al. "Dual-Responsive Biomimetic Nanoplatform for Cascade Synergistic Therapy of Endometrial Cancer." ACS Appl Bio Mater. September 7, 2026. PMID 42702983. https://doi.org/10.1021/acsabm.6c00563 (subscription access)

114. Chen J, et al. "Histone demethylase KDM4A promotes endometrial cancer progression through an ERRγ-associated cell-cycle regulatory axis." Int J Biol Sci. September 3, 2026. PMID 42807380. https://doi.org/10.7150/ijbs.133986 (license unconfirmed)

115. Huang TT, et al. "DHX9 Inhibition Enhances Paclitaxel Sensitivity by Inducing Mitotic Failure in Ovarian and Endometrial Cancers." Mol Cancer Ther. September 2, 2026. PMID 41873535. https://doi.org/10.1158/1535-7163.MCT-25-1196 (subscription access)

116. Baron M, et al. "[Endometrial Cancer: From Clinical Diagnosis to Treatment Strategy]." Soins. September 2026. PMID 42728010. https://doi.org/10.1016/j.soin.2026.07.016 (subscription access)

117. Wang MH, et al. "Inhibition of Cyclin-dependent Kinase Counteracts Neuron-promoted Bladder and Endometrial Tumorigenesis: A Systematic Analysis." In Vivo. September 2026. PMID 42665397. https://doi.org/10.21873/invivo.14427 (license unconfirmed)

118. Tong Y, et al. "The N6-Methyladenosine-Modified CIT Promotes Uterine Corpus Endometrial Carcinoma Progression by Inhibiting the Hippo Signaling Pathway." Immunol Cell Biol. September 2026. PMID 42565639. https://doi.org/10.1111/imcb.70152 (subscription access)

119. Li J, et al. "KLF12-mediated suppression of androgen receptor accelerates metastasis in endometrioid endometrial carcinoma by activating epithelial-mesenchymal transition." Oncogene. September 2026. PMID 42493546. https://doi.org/10.1038/s41388-026-03899-2 (license unconfirmed)

120. Richey A, et al. "Identification of genomic features that uniquely impact estrogen receptor alpha binding and its effects on gene expression in endometrial cancer." Genome Res. September 1, 2026. PMID 42469015. https://doi.org/10.1101/gr.281792.125 (license unconfirmed)

121. Shao J, et al. "The ubiquitin ligase LONRF2 inhibits glycolysis and malignant phenotypes in endometrial cancer through aldolase a degradation." J Biol Chem. September 2026. PMID 42442502. https://doi.org/10.1016/j.jbc.2026.113325 (license unconfirmed)

122. El-Sehrawy AAMA, et al. "Estrobolome and the endocrine-microbiome axis in breast and endometrial carcinogenesis." Crit Rev Oncol Hematol. September 2026. PMID 42401355. https://doi.org/10.1016/j.critrevonc.2026.105471 (subscription access)

123. Karabacak E, Hacioglu C. "Targeting the SOX11/GPX4/SLC7A11 Axis: A Novel Mechanism for Boric Acid-Induced Ferroptosis in Endometrial Cancer." Biol Trace Elem Res. September 2026. PMID 42178444. https://doi.org/10.1007/s12011-026-05158-7 (license unconfirmed)

124. Benbrook DM, et al. "Recent advancements in gynecologic cancer research: a SPORE investigators meeting report." J Natl Cancer Inst. September 15, 2026. PMID 42745474. https://doi.org/10.1093/jnci/djag319 (subscription access)

125. El Hajj H, et al. "Best original research presented at the 27th European Congress on Gynaecological Oncology: best of ESGO 2026." Int J Gynecol Cancer. September 2026. PMID 42541943. https://doi.org/10.1016/j.ijgc.2026.104875 (subscription access)

A note on how this digest was made: This edition was built by searching PubMed for papers published in September 2026, using targeted searches across the uterine and endometrial cancer landscape (molecular classification, immunotherapy and targeted therapy, surgery and staging, uterine sarcoma, fertility preservation, survivorship, and disparities) plus a dedicated qualitative search. Papers summarized in full are open-access under a permitted license (CC0, CC BY, CC BY-SA, CC BY-ND, or CC BY-NC); on-topic papers under other licenses are listed by citation only. A companion methodology report, available separately, documents the full search-and-screening process and every paper reviewed.